Consider an earlier switch for patients with intolerance and/or suboptimal response.
Patients with intolerance may need a treatment switch. Some persistent side effects can impact compliance with therapy, which in turn can lead to poor outcomes.7,8
Patients who experience suboptimal response may need a different treatment strategy.2,9,10
ATP, adenosine 5’-triphosphate; CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.
References: 1. Soverini S, Gnani A, Colarossi S, et al. Blood. 2009;114(10):2168-2171. 2. Garg RJ, Kantarjian H, O'Brien S, et al. Blood. 2009;114(20):4361-4368. 3. Ibrahim AR, Paliompeis C, Bua M, et al. Blood. 2010;116(25):5497-5500. 4. Gambacorti-Passerini C, Brümmendorf TH, Kim D-W, et al. Am J Hematol. 2014;89(7):732-742. 5. Shah NP, Kim D-W, Kantarjian H, et al. Haematologica. 2010;95(2):232-240. 6. Kantarjian HM, Giles FJ, Bhalla KN, et al. Blood. 2011;117(4):1141-1145. 7. Marin D, Bazeos A, Mahon F-X, et al. J Clin Oncol. 2010;28(14):2381-2388. 8. Kim D-W, Saussele S, Williams LA, et al. Ann Hematol. 2018;97(8):1357-1367. 9. Bosi GR, Fogliatto LM, Costa TEV, et al. Hematol Transfus Cell Ther. 2019;41(3):222-228. 10. Iacob RE, Zhang J, Gray NS, Engen JR. PLoS One. 2011;6(1):e15929.